ACS Medicinal Chemistry Letters

Letter

Cite This: ACS Med. Chem. Lett. 2019, 10, 960−965

pubs.acs.org/acsmedchemlett

Modifications at Arg and Ile Give Neurotensin(8−13) Derivatives with High Stability and Retained NTS_1 Receptor Affinity

Lisa Schindler, Günther Bernhardt, and Max Keller*

Institute of Pharmacy, Faculty of Chemistry and Pharmacy, University of Regensburg, Universitätsstrasse 31, D-93053 Regensburg, Germany

Supporting Information

ABSTRACT: Due to its expression in various malignant tumors, the neurotensin receptor 1 (NTS_1R) has been suggested and explored as a target for tumor diagnosis and therapy. Animal model-based investigations of various radiolabeled NTS_1R ligands derived from the hexapeptide neurotensin(8−13) (NT(8−13)), e.g. ^{68}Ga- and ^{18}F-labeled compounds for PET diagnostics, give rise to optimize such radiotracers for clinical use. As NT(8−13) is rapidly degraded in vivo; structural modifications are required in terms of increased metabolic stability. In this study, the stabilization of the peptide backbone of NT(8−13) against enzymatic degradation was systematically explored by performing an *N*-methyl scan, replacing Ile^{12} by *tert*-butylglycine^{12} (Tle^{12}) and N-terminal acylation. *N*-Methylation of either arginine, Arg^8, or Arg^9, combined with the Ile^{12}/Tle^{12} exchange, proved to be most favorable with respect to NTS_1R affinity (K_i < 2 nM) and stability in human plasma ($t_{1/2}$ > 48 h), a valuable result regarding the development of radiopharmaceuticals derived from NT(8−13).



KEYWORDS: *Peptide, neurotensin, NT(8−13), neurotensin receptor, plasma stability*

The neuromodulator neurotensin (NT), a 13 amino acid peptide (Figure 1), is found in the central nervous system (CNS), mediating e.g. analgesic effects, as well as in the periphery (primarily in the gastrointestinal tract).[1,2] The carboxy-terminal hexapeptide of NT (NT(8−13) (**1**), Figure 1), is biologically equi-active to NT.[3] The physiological effects of NT are mediated by three cell-surface receptors: the NT receptors 1 and 2 (NTS_1R, NTS_2R), both G-protein coupled receptors,[4] and the NTS_3R, which belongs to the Vps10p-domain receptor family.[2,5] The NTS_1R has increasingly gained interest as a target for tumor diagnosis and therapy, as it was reported to be (over)expressed in a variety of malignancies, among them the prognostically poor pancreatic adenocarcinoma, Ewing's sarcoma, breast cancer, and colorectal carcinoma.[6−9] Thus, radiolabeled NTS_1R ligands harbor the potential of being used as radiopharmaceuticals. The majority of such compounds (e.g., ^{68}Ga- and ^{18}F-labeled for PET diagnostics, ^{177}Lu-labeled for radioendotherapy) has been derived from the agonist **1**.[10−19] Noteworthily, also NTS_1R ligands derived from nonpeptidic antagonists have been explored as radiodiagnostics and radiotherapeutics.[20,21] Recently reported data of a clinical trial on the treatment of pancreatic adenocarcinoma in men by ^{177}Lu-labeled NTS_1R antagonists give reason to develop clinical trial candidates with improved properties.[22] Therefore, peptidic NTS_1R ligands, such as radiolabeled derivatives of **1**, should be considered for clinical trials.



Figure 1. Amino acid sequences of neurotensin, **1** (NT(8−13), in blue) and **2**, as well as major enzymatic cleavage sites (in red) of **1**.[3,24,25] EC 3.4.24.15: metalloendopeptidase 24.15, EC 3.4.24.16: metalloendopeptidase 24.16, EC 3.4.24.11: neutral endopeptidase 24.11, EC 3.4.15.1: angiotensin converting enzyme (ACE).[24,25] [a]Barroso et al.[41] [b]Keller et al.[42]

A major drawback of peptide **1** is its rapid degradation in vivo by peptidases (see Figure 1).[23,24] Enzymatic degradation of **1** occurs at three major sites: the Arg^8−Arg^9 bond, the Pro^{10}−Tyr^{11} bond, and the bond between Tyr^{11} and Ile^{12} (*cf.* Figure 1).[24,25] The predominant approaches to stabilize the backbone of **1** are *N*-methylation of Arg^8 or Arg^9, N-terminal acylation, and the exchange of Ile^{12} by *tert*-butylglycine (Tle).[10−15,17,26−38] However, for some interesting analogs

Received: March 20, 2019
Accepted: May 10, 2019
Published: May 10, 2019

© 2019 American Chemical Society

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960−965

Scheme 1. Syntheses of the NT(8−13) Derivatives 2−9, 11, and 12[a]



compd.	n	R1	R2	R3	R4	R5	A
2	3	H	H	H	H	H	*tert*-butyl
3	3	CH_3	H	H	H	H	(*S*)-1-methylpropyl
4	3	H	CH_3	H	H	H	(*S*)-1-methylpropyl
5	3	H	H	CH_3	H	H	(*S*)-1-methylpropyl
6	3	H	H	H	CH_3	H	(*S*)-1-methylpropyl
7	3	CH_3	H	H	H	H	*tert*-butyl
8	3	H	CH_3	H	H	H	*tert*-butyl
9	3	H	H	H	H	CH_3	(*S*)-1-methylpropyl
11	2	CO-C_2H_5	H	H	H	H	(*S*)-1-methylpropyl
12	2	CO-C_2H_5	H	H	H	H	*tert*-butyl

[a]Reagents and conditions: (I) Fmoc strategy SPPS using HBTU/HOBt and DIPEA, solvent: DMF/NMP (80:20 v/v), 35 °C, 2 × 1 h or 2 × 2 h, Fmoc-deprotection: 20% piperidine in DMF/NMP (80:20 v/v), rt, 2 × 8−10 min; (II) (1) hexafluoro-2-propanol (HFIP)/CH_2Cl_2 (1:3 v/v), rt, 2 × 20 min, (2) TFA/H_2O (95:5 v/v), rt, 3 h; (III) DIPEA, solvent: CH_2Cl_2, 35 °C, 14 h; (IV) DIPEA, solvent: DMF/NMP (80:20 v/v), rt, 1 h; overall yields 77% (**2**), 67% (**3**), 56% (**4**), 18% (**5**), 15% (**6**), 42% (**7**), 38% (**8**), 20% (**9**), 56% (**11**), 85% (**12**).

of **1**, such as *N*-methylated derivatives, investigations on the stability are lacking.[33,39] It is worth mentioning that described derivatives of **1**, containing Tle[12] instead of Ile[12], include additional structural modifications throughout;[10−12,29,31,32,38,40] that is, [Tle[12]]NT(8−13) (**2**, *cf.* Figure 1) has not been reported to date to the best of the authors' knowledge. Therefore, it is difficult to estimate the impact of the Ile[12]/Tle[12] exchange on the stability of Tle[12]-containing derivatives of **1**.

Aiming at a systematic study on the stabilization of the NT(8−13) core structure, we synthesized compound **2**, performed an *N*-methyl scan of **1**, combined *N*-methylation with the Ile[12]/Tle[12] exchange, and, additionally, prepared N-terminally acylated derivatives of **1**. All compounds were studied with respect to NTS_1R binding and plasma stability.

Peptides **2**, **3**,[34] **4**,[33] **5**,[33,39] **6**,[33] **7**, **8**, and **9**[33] were prepared by solid-phase peptide synthesis (SPPS) according to the 9-fluorenylmethoxycarbonyl (Fmoc) protecting group strategy using 1-hydroxybenzotriazole (HOBt)/*O*-(1*H*-benzotriazol-1-yl)-*N*,*N*,*N*′,*N*′-tetramethyluronium hexafluorophosphate (HBTU) and diisopropylethylamine (DIPEA) for amide bond formation (Scheme 1). Coupling of Fmoc-protected amino acids to the secondary amino group of *N*-methylated amino acids turned out to be the yield limiting factor in the cases of **5**, **6**, and **9** (overall yields 18%, 15%, and 20%, respectively). The N-terminally propionylated derivative **11** was obtained by treatment of the respective resin-bound, side chain-protected, but N-terminally deprotected precursor peptide with succinimidyl propionate (**10**) followed by cleavage off the resin and side chain deprotection. By contrast, the N-terminally propionylated peptide **12** was prepared by solution phase treatment of **2** with compound **10** (Scheme 1).

NTS_1R binding data (K_i values) were determined for **1**−**9**, **11**, and **12** by competition binding with [^{3}H]UR-MK300[42] ([^{3}H]**13**, for structure see Figure S1, Supporting Information) at intact $hNTS_1R$ expressing HT-29 colon carcinoma cells (Table 1). The replacement of Ile[12] by Tle[12] in **1** (compound **2**) resulted in a minor decrease in NTS_1R affinity (K_i values of **1** and **2**: 0.33 vs 1.17 nM, *cf.* Table 1). Regarding the *N*-methyl scan of **1** (peptides **3**−**6** and **9**), methylation at Arg[8] or Arg[9] (**3**, **4**) did not affect NTS_1R affinity (K_i < 0.5 nM, Table 1). By contrast, *N*-methylation of Tyr[11], Ile[12], or Leu[13] (**5**, **6**, **9**) led to a considerable decrease in NTS_1R affinity (K_i values: > 1,000 nM, 60 nM and 880 nM, respectively, *cf.* Table 1). As expected, the combination of the *N*-methylation at Arg[8] or Arg[9] with the

Table 1. Peptide Sequences and NTS_1R Affinities of 1−9, 11, and 12, as Well as Stabilities of 1−9, 11, and 12 in Human Plasma/PBS (1:2 v/v) (37 °C)

compd	sequence	K_i [nM] NTS_1R[a]	% intact peptide in plasma[b] after the specified incubation times: 10 min	30 min	1 h	2 h	6 h	24 h	48 h
1	Arg-Arg-Pro-Tyr-Ile-Leu	0.33 [0.35, 0.31] (lit. 0.14[c])	23.1 ± 0.2	n.d.	<1	n.d.	n.d.	<1	<1
2	Arg-Arg-Pro-Tyr-Tle-Leu	1.17 [1.17, 1.17]	10.8 ± 0.5	n.d.	<1	n.d.	n.d.	<1	<1
3	N(Me)-Arg-Arg-Pro-Tyr-Ile-Leu	0.223 ± 0.005(lit. 0.29[d])	92.1 ± 0.1	88.2 ± 0.2	79.7 ± 0.1	70.8 ± 0.1	n.d.	n.d.	n.d.
4	Arg-N(Me)-Arg-Pro-Tyr-Ile-Leu	0.29 ± 0.03(lit. 0.51[e])	>99	93.6 ± 0.1	83.7 ± 0.3	66.4 ± 0.1	n.d.	n.d.	n.d.
5	Arg-Arg-Pro-N(Me)-Tyr-Ile-Leu	>1,000(lit. 5,100[e])	22.9 ± 0.2	<1	<1	<1	n.d.	n.d.	n.d.
6	Arg-Arg-Pro-Tyr-N(Me)-Ile-Leu	60 ± 5(lit. 160[e])	2.6 ± 0.5	<1	<1	<1	n.d.	n.d.	n.d.
7	N(Me)-Arg-Arg-Pro-Tyr-Tle-Leu	0.88 ± 0.13	n.d.	n.d.	>99	n.d.	>99	98.3 ± 0.8	86.8 ± 0.3
8	Arg-N(Me)-Arg-Pro-Tyr-Tle-Leu	1.6 ± 0.1	n.d.	n.d.	>99	n.d.	>99	>99	>99
9	Arg-Arg-Pro-Tyr-Ile-N(Me)-Leu	880 ± 260(lit. 190[e])	39.9 ± 0.9	<1	<1	<1	n.d.	n.d.	n.d.
11	Propionyl-Arg-Arg-Pro-Tyr-Ile-Leu	1.0 ± 0.2	>99	84.0 ± 0.1	71.8 ± 0.2	32.4 ± 0.1	n.d.	n.d.	n.d.
12	Propionyl-Arg-Arg-Pro-Tyr-Tle-Leu	18 ± 2	n.d.	n.d.	>99	n.d.	>99	>99	92.5 ± 0.9

[a]Determined by radioligand competition binding with [^{3}H]**13** at HT-29 cells; mean values from two (**1**, **2**), three (**3**, **4**) or four (**6**−**9**, **11**, **12**) independent experiments, each performed in triplicate (for *n* > 2 K_i values are given ± SEM; in the case of *n* = 2 individual K_i values are given in square brackets). [b]The initial concentration of the peptides in plasma/PBS (1:2 v/v) was 100 μM; presented are mean values ± SEM from three independent experiments (SEM not given if no decomposition was observed). [c]Keller et al.[42] [d]Orwig et al.[34] [e]Härterich et al.[33] n.d. = not determined.

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960−965

replacement of Ile^{12} by Tle^{12} (peptides **7** and **8**) resulted in NTS_1R affinities comparable to that of **2** (Table 1). The N-terminally propionylated analogs of **1** and **2** (compounds **11** and **12**) exhibited K_i values (NTS_1R) of 1.0 and 18 nM, respectively.

Figure 2 illustrates a general decrease in NTS_1R affinity caused by the replacement of Ile^{12} by Tle^{12} in **1**, **3**, **4**, and **11**, giving **2**, **7**, **8**, and **12**, respectively, and a dependency of the extent of the decrease in affinity on the primary structure of the peptides. This is in agreement with reported NTS_1R binding data of derivatives of **1** containing Tle^{12}.[10,11,27,31,38,40]



Figure 2. Decrease in NTS_1R affinity (increase in K_i) resulting from the exchange of Ile^{12} by Tle^{12} in **1**, **3**, **4**, and **11** (black bars) giving **2**, **7**, **8**, and **12** (gray bars), respectively. Note: the scales of the *Y*-axes are different.

In order to investigate the effect of *N*-methylation (**3**–**9**), Ile^{12}/Tle^{12} exchange (**2**, **7**, **8**, **12**), and N-terminal acylation (**11**, **12**) on the stability of the peptides against enzymatic cleavage, the stability of all compounds was investigated in human plasma at 37 °C for up to 48 h (Figure 3, Table 1). Whereas *N*-methylation of Arg^8 or Arg^9 in **1** (compounds **3** and **4**) significantly enhanced the peptide stability in plasma compared to **1**, methylation of Tyr^{11}, Ile^{12}, and Leu^{13} (**5**, **6**, **9**) did not lead to higher plasma stabilities. Strikingly, peptide **2**, which differed from **1** only with respect to the replacement of Ile^{12} by Tle^{12}, proved to be as unstable as **1** (Figure 3, Table 1). However, the combination of the Ile^{12}/Tle^{12} exchange with *N*-methylation of Arg^8 or Arg^9 (**7**, **8**) resulted in significantly higher plasma stabilities ($t_{1/2}$ > 48 h) compared to **3** and **4**. These results confirmed that both N-terminal (cleavage between Arg^8 and Arg^9) and C-terminal (cleavage between Tyr^{11} and Ile^{12}) degradation are highly relevant, and they revealed that the former occurs faster than the latter. As in the case of N-terminal methylation of **1** (peptide **3**), N-terminal propionylation of **1** (peptide **11**) resulted in a moderate increase in enzymatic stability compared to **1** ($t_{1/2}$ of **11** between 1 and 2 h, *cf.* Table 1). The combination of N-terminal propionylation with an Ile^{12}/Tle^{12} exchange (compound **12**) led to an excellent plasma stability as also observed in the case of combining N-terminal methylation with an Ile^{12}/Tle^{12} exchange (peptide **7**) (Figure 3, Table 1).

Figure 4 provides an overview of the major degradation fragments identified by LC-HRMS. The Arg^8–Arg^9, Pro^{10}–Tyr^{11}, and Tyr^{11}–Ile^{12} bonds were identified as the major cleavage sites (Figure 4), being in agreement with reported data on the metabolic stability of **1**.[24,25] As outlined above, the present study suggests that cleavage of Arg^8 in **1** occurs faster than its C-terminal degradation. This is, on the one hand, in agreement with reports in the literature;[24] on the other hand, it is in disagreement with other reports, which suggest an Ile^{12}/Tle^{12} exchange as the most crucial structural modification with respect to metabolic stabilization.[27,28]

In conclusion, the synthesis and investigation of *N*-methylated derivatives of NT(8–13) (**1**), N-terminally acylated derivatives of **1**, and analogs containing Tle^{12} instead of Ile^{12} revealed that only the combination of appropriate N-terminal (e.g., *N*-methylation



Figure 3. Stabilities of **1**–**9**, **11**, and **12** in human plasma/PBS (1:2 v/v) at 37 °C investigated for up to 48 h. Data represent mean values ± SEM from three independent experiments.

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960–965



Identified fragments after incubation in human plasma/PBS (1:2 v/v):

compd.	R^1	R^2	R^3	R^4	R^5	A	F1	F2	F3	F4
1	H	H	H	H	H	(*S*)-1-methylpropyl	x	x		
2	H	H	H	H	H	*tert*-butyl	x	x		
3	CH_3	H	H	H	H	(*S*)-1-methylpropyl			x	x
4	H	CH_3	H	H	H	(*S*)-1-methylpropyl			x	x
5	H	H	CH_3	H	H	(*S*)-1-methylpropyl	x			
6	H	H	H	CH_3	H	(*S*)-1-methylpropyl	x	x		
7	CH_3	H	H	H	H	*tert*-butyl				
8	H	CH_3	H	H	H	*tert*-butyl				
9	H	H	H	H	CH_3	(*S*)-1-methylpropyl	x	x		x
11	$CO\text{-}C_2H_5$	H	H	H	H	(*S*)-1-methylpropyl			x	x
12	$CO\text{-}C_2H_5$	H	H	H	H	*tert*-butyl		x		x

Figure 4. Major enzymatic cleavage sites (C1−C3) of compounds **1**−**9**, **11**, and **12** as well as corresponding fragments F1−F4, identified by LC-HRMS analysis after incubation in human plasma at 37 °C for up to 48 h.

of Arg[8]) and C-terminal (replacement of Ile[12] by Tle[12]) structural modifications in **1** affords highly stable (plasma half-live >48 h) congeners of **1** (compounds **7**, **8**, and **12**). Fortunately, two of the most stable compounds (**7**, **8**) exhibited the highest NTS_1R affinities of the investigated analogs of **1**. This work answers open questions concerning the controversially discussed impact of various structural modifications of **1** on the enzymatic stability, thus supporting the development of stable radiolabeled derivatives of **1**, which harbor the potential of being used as radiopharmaceuticals.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.9b00122.

General experimental conditions; experimental synthetic protocols and analytical data of compounds **2**−**9**, **11**, and **12**; radioligand competition binding assay; experimental protocol for the investigation of the stability of **2**−**9**, **11**, and **12** in human plasma; Figures S1 and S2; RP-HPLC chromatograms of compounds **2**−**9**, **11**, and **12**; ^1H NMR spectra of compounds **2**−**9**, **11**, and **12** in DMSO-d_6 and DMSO-d_6/D_2O (PDF)

Molecular formula strings (XLSX)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: max.keller@ur.de. Phone: (+49)941-9433329. Fax: (+49)941-9434820.

ORCID

Günther Bernhardt: 0000-0001-6491-9874

Max Keller: 0000-0002-8095-8627

Author Contributions

L.S. performed any syntheses, radioligand competition binding experiments, and plasma stability studies. M.K. initiated and planned the project. M.K. and G.B. supervised the research. L.S., M.K., and G.B. wrote the manuscript. All authors have given approval to the final version of the manuscript.

Funding

This work was funded by the Deutsche Forschungsgemeinschaft (research grant KE 1857/1-1 and 1-2, Graduate Training Program (Graduiertenkolleg) GRK1910)

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Susanne Bollwein, Brigitte Wenzl, and Maria Beer-Krön for excellent technical assistance, Christoph Müller for the synthesis of compound **10**, and Armin Buschauer for providing laboratory equipment.

■ ABBREVIATIONS

2-ClTrt, 2-chlorotrityl; 2-ClTrt-Cl, 2-chlorotrityl-chloride; DIPEA, diisopropylethylamine; FCS, fetal calf serum; Fmoc, 9-fluorenylmethoxycarbonyl; HBTU, *O*-(1*H*-benzotriazol-1-yl)-*N*,*N*,*N'*,*N'*-tetramethyluronium hexafluorophosphate; HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; HOBt, 1-hydroxybenzotriazole; HT-29, human colorectal adenocarcinoma cell line; IC_{50}, inhibitor/antagonist concentration which suppresses 50% of an agonist induced effect, or displaces 50% of a labeled ligand from the binding site; *k*, retention (or capacity) factor (HPLC); K_d, dissociation constant obtained from a saturation binding experiment; K_i, dissociation constant obtained from a competition binding experiment; NT, neurotensin; NT(8−13), neurotensin(8−13); NTS_1R, neurotensin receptor 1; NTS_2R, neurotensin receptor 2; RP, reversed phase; SEM, standard error of the mean; SPPS, solid-phase peptide synthesis; Tle, *tert*-butylglycine

■ REFERENCES

(1) Myers, R. M.; Shearman, J. W.; Kitching, M. O.; Ramos-Montoya, A.; Neal, D. E.; Ley, S. V. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. *ACS Chem. Biol.* **2009**, *4*, 503−525.

(2) Vincent, J.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. *Trends Pharmacol. Sci.* **1999**, *20*, 302−309.

(3) Carraway, R.; Leeman, S. E. The amino acid sequence of a hypothalamic peptide, neurotensin. *J. Biol. Chem.* **1975**, *250*, 1907−1911.

(4) Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. *Neuron* **1990**, *4*, 847−854.

(5) Mazella, J.; Zsürger, N.; Navarro, V.; Chabry, J.; Kaghad, M.; Caput, D.; Ferrara, P.; Vita, N.; Gully, D.; Maffrand, J. P.; Vincent, J. P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. *J. Biol. Chem.* **1998**, *273*, 26273−26276.

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960−965

(6) Maoret, J.-J.; Pospai, D.; Rouyer-Fessard, C.; Couvineau, A.; Laboisse, C.; Voisin, T.; Laburthe, M. Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. *Biochem. Biophys. Res. Commun.* **1994**, *203*, 465−471.
(7) Reubi, J. C.; Waser, B.; Friess, H.; Büchler, M.; Laissue, J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. *Gut* **1998**, *42*, 546−550.
(8) Reubi, J. C.; Waser, B.; Schaer, J.; Laissue, J. A. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcoma. *Int. J. Cancer* **1999**, *82*, 213−218.
(9) Souazé, F.; Dupouy, S.; Viardot-Foucault, V.; Bruyneel, E.; Attoub, S.; Gespach, C.; Gompel, A.; Forgez, P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. *Cancer Res.* **2006**, *66*, 6243−6249.
(10) Bergmann, R.; Scheunemann, M.; Heichert, C.; Mäding, P.; Wittrisch, H.; Kretzschmar, M.; Rodig, H.; Tourwé, D.; Iterbeke, K.; Chavatte, K.; Zips, D.; Reubi, J. C.; Johannsen, B. Biodistribution and catabolism of ^{18}F-labeled neurotensin(8−13) analogs. *Nucl. Med. Biol.* **2002**, *29*, 61−72.
(11) Alshoukr, F.; Rosant, C.; Maes, V.; Abdelhak, J.; Raguin, O.; Burg, S.; Sarda, L.; Barbet, J.; Tourwé, D.; Pelaprat, D.; Gruaz-Guyon, A. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors. *Bioconjugate Chem.* **2009**, *20*, 1602−1610.
(12) García-Garayoa, E.; Bläuenstein, P.; Blanc, A.; Maes, V.; Tourwé, D.; Schubiger, P. A. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. *Eur. J. Nucl. Med. Mol. Imaging* **2009**, *36*, 37−47.
(13) Maschauer, S.; Einsiedel, J.; Hocke, C.; Hübner, H.; Kuwert, T.; Gmeiner, P.; Prante, O. Synthesis of a ^{68}Ga-labeled peptoid-peptide hybrid for imaging of neurotensin receptor expression in vivo. *ACS Med. Chem. Lett.* **2010**, *1*, 224−228.
(14) Maschauer, S.; Einsiedel, J.; Haubner, R.; Hocke, C.; Ocker, M.; Hübner, H.; Kuwert, T.; Gmeiner, P.; Prante, O. Labeling and Glycosylation of Peptides Using Click Chemistry: A general approach to ^{18}F-glycopeptides as effective imaging probes for positron emission tomography. *Angew. Chem., Int. Ed.* **2010**, *49*, 976−979.
(15) Alshoukr, F.; Prignon, A.; Brans, L.; Jallane, A.; Mendes, S.; Talbot, J.-N.; Tourwé, D.; Barbet, J.; Gruaz-Guyon, A. Novel DOTA-neurotensin analogues for ^{111}In scintigraphy and ^{68}Ga PET imaging of neurotensin receptor-positive tumors. *Bioconjugate Chem.* **2011**, *22*, 1374−1385.
(16) Maschauer, S.; Ruckdeschel, T.; Tripal, P.; Haubner, R.; Einsiedel, J.; Hübner, H.; Gmeiner, P.; Kuwert, T.; Prante, O. In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study. *Pharmaceuticals* **2014**, *7*, 464−481.
(17) Jia, Y.; Shi, W.; Zhou, Z.; Wagh, N. K.; Fan, W.; Brusnahan, S. K.; Garrison, J. C. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting. *Nucl. Med. Biol.* **2015**, *42*, 816−823.
(18) Maschauer, S.; Einsiedel, J.; Hübner, H.; Gmeiner, P.; Prante, O. ^{18}F- and ^{68}Ga-labeled neurotensin peptides for PET imaging of neurotensin receptor 1. *J. Med. Chem.* **2016**, *59*, 6480−6492.
(19) Deng, H.; Wang, H.; Zhang, H.; Wang, M.; Giglio, B.; Ma, X.; Jiang, G.; Yuan, H.; Wu, Z.; Li, Z. Imaging neurotensin receptor in prostate cancer with ^{64}Cu-labeled neurotensin analogs. *Mol. Imaging* **2017**, *16*, 1536012117711369.
(20) Lang, C.; Maschauer, S.; Hübner, H.; Gmeiner, P.; Prante, O. Synthesis and evaluation of a ^{18}F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors. *J. Med. Chem.* **2013**, *56*, 9361−9365.
(21) Schulz, J.; Rohracker, M.; Stiebler, M.; Goldschmidt, J.; Grosser, O. S.; Osterkamp, F.; Pethe, A.; Reineke, U.; Smerling, C.; Amthauer, H. Comparative evaluation of the biodistribution profiles of a series of nonpeptidic neurotensin receptor-1 antagonists reveals a promising candidate for theranostic applications. *J. Nucl. Med.* **2016**, *57*, 1120−1123.
(22) Baum, R. P.; Singh, A.; Schuchardt, C.; Kulkarni, H. R.; Klette, I.; Wiessalla, S.; Osterkamp, F.; Reineke, U.; Smerling, C. ^{177}Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. *J. Nucl. Med.* **2018**, *59*, 809−814.
(23) Pedersen, J. H.; Beck, H.; Shokouh-Amiri, M.; Fischer, A. Effect of neurotensin in the dumping syndrome. *Scand. J. Gastroenterol.* **1986**, *21*, 478−482.
(24) García-Garayoa, E.; Allemann-Tannahill, L.; Bläuenstein, P.; Willmann, M.; Carrel-Rémy, N.; Tourwé, D.; Iterbeke, K.; Conrath, P.; Schubiger, P. A. In vitro and in vivo evaluation of new radiolabeled neurotensin(8−13) analogues with high affinity for NT1 receptors. *Nucl. Med. Biol.* **2001**, *28*, 75−84.
(25) Kitabgi, P.; De Nadai, F.; Rovère, C.; Bidard, J. N. Biosynthesis, maturation, release, and degradation of neurotensin and neuromedin N. *Ann. N. Y. Acad. Sci.* **1992**, *668*, 30−42.
(26) Tyler-McMahon, B. M.; Boules, M.; Richelson, E. Neurotensin: peptide for the next millennium. *Regul. Pept.* **2000**, *93*, 125−136.
(27) Bruehlmeier, M.; García-Garayoa, E.; Blanc, A.; Holzer, B.; Gergely, S.; Tourwé, D.; Schubiger, P. A.; Bläuenstein, P. Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. *Nucl. Med. Biol.* **2002**, *29*, 321−327.
(28) García-Garayoa, E.; Bläuenstein, P.; Bruehlmeier, M.; Blanc, A.; Iterbeke, K.; Conrath, P.; Tourwé, D.; Schubiger, P. A. Preclinical evaluation of a new, stabilized neurotensin(8−13) pseudopeptide radiolabeled with ^{99m}Tc. *J. Nucl. Med.* **2002**, *43*, 374−383.
(29) Bläuenstein, P.; García-Garayoa, E.; Rüegg, D.; Blanc, A.; Tourwé, D.; Beck-Sickinger, A.; Schubiger, P. A. Improving the tumor uptake of ^{99m}Tc-labeled neuropeptides using stabilized peptide analogues. *Cancer Biother.Radiopharm.* **2004**, *19*, 181−188.
(30) Maes, V.; García-Garayoa, E.; Bläuenstein, P.; Tourwé, D. Novel ^{99m}Tc-labeled neurotensin analogues with optimized biodistribution properties. *J. Med. Chem.* **2006**, *49*, 1833−1836.
(31) Nock, B. A.; Nikolopoulou, A.; Reubi, J. C.; Maes, V.; Conrath, P.; Tourwé, D.; Maina, T. Toward stable N_4-modified neurotensins for NTS_1-receptor-targeted tumor imaging with ^{99m}Tc. *J. Med. Chem.* **2006**, *49*, 4767−4776.
(32) Maina, T.; Nikolopoulou, A.; Stathopoulou, E.; Galanis, A. S.; Cordopatis, P.; Nock, B. A. [^{99m}Tc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: synthesis and preclinical results. *Eur. J. Nucl. Med. Mol. Imaging* **2007**, *34*, 1804−1814.
(33) Härterich, S.; Koschatzky, S.; Einsiedel, J.; Gmeiner, P. Novel insights into GPCR—Peptide interactions: Mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1. *Bioorg. Med. Chem.* **2008**, *16*, 9359−9368.
(34) Orwig, K. S.; Lassetter, M. R.; Hadden, M. K.; Dix, T. A. Comparison of N-terminal modifications on neurotensin(8−13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. *J. Med. Chem.* **2009**, *52*, 1803−1813.
(35) Boules, M.; Liang, Y.; Briody, S.; Miura, T.; Fauq, I.; Oliveros, A.; Wilson, M.; Khaniyev, S.; Williams, K.; Li, Z.; Qi, Y.; Katovich, M.; Richelson, E. NT79: A novel neurotensin analog with selective behavioral effects. *Brain Res.* **2010**, *1308*, 35−46.
(36) Einsiedel, J.; Held, C.; Hervet, M.; Plomer, M.; Tschammer, N.; Hübner, H.; Gmeiner, P. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics. *J. Med. Chem.* **2011**, *54*, 2915−2923.
(37) Held, C.; Plomer, M.; Hübner, H.; Meltretter, J.; Pischetsrieder, M.; Gmeiner, P. Development of a metabolically stable neurotensin receptor 2 (NTS2) ligand. *ChemMedChem* **2013**, *8*, 75−81.
(38) Mascarin, A.; Valverde, I. E.; Mindt, T. L. Structure-activity relationship studies of amino acid substitutions in radiolabeled neurotensin conjugates. *ChemMedChem* **2016**, *11*, 102−107.
(39) Bittermann, H.; Einsiedel, J.; Hübner, H.; Gmeiner, P. Evaluation of lactam-bridged neurotensin analogues adjusting ψ(Pro^{10}) close to the experimentally derived bioactive conformation of NT(8−13). *J. Med. Chem.* **2004**, *47*, 5587−5590.

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960−965

(40) Kokko, K. P.; Hadden, M. K.; Orwig, K. S.; Mazella, J.; Dix, T. A. In vitro analysis of stable, receptor-selective neurotensin[8−13] analogues. *J. Med. Chem.* **2003**, *46*, 4141−4148.
(41) Barroso, S.; Richard, F.; Nicolas-Ethève, D.; Reversat, J. L.; Bernassau, J. M.; Kitabgi, P.; Labbé-Jullié, C. Identification of residues involved in neurotensin binding and modeling of the agonist binding site in neurotensin receptor 1. *J. Biol. Chem.* **2000**, *275*, 328−336.
(42) Keller, M.; Kuhn, K. K.; Einsiedel, J.; Hübner, H.; Biselli, S.; Mollereau, C.; Wifling, D.; Svobodova, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P. M.; Gmeiner, P.; Buschauer, A. Mimicking of Arginine by functionalized N^{ω}-carbamoylated arginine as a new broadly applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, neuropeptide FF, and neurotensin receptor ligands as examples. *J. Med. Chem.* **2016**, *59*, 1925−1945.

DOI: 10.1021/acsmedchemlett.9b00122
ACS Med. Chem. Lett. 2019, 10, 960−965